# Dianliang Napu

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dianliang-napu

- Industry: Biotechnology
- Headquarters: Kunshan
- Latest round: Series A (Sep 25, 2025)
- Investors on record: 1

## About

Founded in 2023 and based in Kunshan, China, Dianliang Napu focused on cutting-edge drug development. In September 2025, Dianliang Napu raised Series A funding from new investor Furen Capital Management.
The company specializes in early-stage drug discovery, core technology development, and preclinical validation. Its pipeline includes proprietary compounds and platform technologies designed to address unmet medical needs.
Dianliang Napu's revenue is generated through licensing of drug candidates, strategic R&D partnerships, and milestone-based agreements with pharmaceutical companies. Additional income may come from government grants and technology transfer arrangements.

## Funding rounds

- Series A, Sep 25, 2025 — Furen Capital Management

## Investors

- Furen Capital Management (https://capitalatlas.ai/funds/furen-capital-management) — Series A